View Rule

View EO 12866 Meetings Printer-Friendly Version     Download RIN Data in XML

DOD/DODOASHA RIN: 0720-AB83 Publication ID: Spring 2022 
Title: TRICARE Coverage of National Institute of Allergy and Infectious Disease Coronavirus Disease 2019 Clinical Trials 
Abstract:

This final rule will publish under the title "TRICARE Coverage and Reimbursement of Certain Services Resulting from Temporary Program Changes in Response to the COVID-19 Pandemic,” related to RINs 0720-AB81 and 0720-AB83.

The following provisions are finalized in a consolidated final rule, with modifications: (1) temporary waiver of the exclusion of audio-only telehealth services during the COVID-19 national emergency; (2) temporary waiver of telehealth cost-sharing during the COVID-19 national emergency; (3) temporary waiver of certain provider licensing requirements during the COVID-19 national emergency; (4) temporary waiver of the three-day prior hospital qualifying stay requirements for skilled nursing facilities during the COVID-19 national emergency; (5) temporary waiver of certain acute care hospital requirements for temporary hospitals and freestanding ambulatory surgery centers during the COVID-19 national emergency; (6) temporary revision of diagnosis related group (DRG) reimbursement at a 20 percent higher rate for COVID-19 patients during the COVID-19 Health and Human Services (HHS) Public Health Emergency (PHE); (7) temporary waiver of certain requirements for Long Term Care Hospitals (LTCHs) during the HHS PHE; (8) the permanent adoption of Medicare’s New Technology Add-On Payments (NTAPs) for new medical items and services; and (9) TRICARE’s enactment of the Medicare Hospital Value Based Purchasing (HVBP) Program.  Two provisions of the TRICARE COVID-19 interim final rules are being addressed in a separate final rule: treatment use of investigational drugs under expanded access; and National Institute for Allergy and Infectious Disease (NIAID) sponsored clinical trials.

 

 

 
Agency: Department of Defense(DOD)  Priority: Other Significant 
RIN Status: Previously published in the Unified Agenda Agenda Stage of Rulemaking: Final Rule Stage 
Major: No  Unfunded Mandates: No 
CFR Citation: 32 CFR 199   
Legal Authority: 5 U.S.C. 301    10 U.S.C. ch 55   
Legal Deadline:  None
Timetable:
Action Date FR Cite
Interim Final Rule  10/30/2020  85 FR 68753   
Interim Final Rule Effective  10/30/2020 
Interim Final Rule Comment Period End  11/30/2020 
Final Action  06/00/2022 
Regulatory Flexibility Analysis Required: Undetermined  Government Levels Affected: Undetermined 
Federalism: No 
Included in the Regulatory Plan: Yes 
RIN Data Printed in the FR: No 
Related RINs: Related to 0720-AB81, Related to 0720-AB82 
Agency Contact:
Erica Ferron
Defense Health Agency, Medical Benefits and Reimbursement Division
Department of Defense
Office of Assistant Secretary for Health Affairs
16401 E Centretech Parkway,
Aurora, CO 80011-9066
Phone:303 676-3626
Email: erica.c.ferron.civ@mail.mil